Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Patrick Yudez

Physician Assistant, Medical Henderson, NV Physician Assistant

NPI 1366152126 CMS profile 11436001

229 N Pecos Rd Ste 100, Henderson, NV 89074

Open in the dashboard

General payments

$6,139

318 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Yudez of Henderson, NV is reported in the CMS Open Payments database as having received $6,139 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $192 8
2024 General $3,536 177
2023 General $2,390 132
2022 General $21 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Yudez
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Patrick Yudez were reported at $192. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Patrick Yudez Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $21 $185 $55–$649 $149
2023 $2,390 $199 $58–$717 $160
2024 $3,536 $206 $62–$740 $164
2025 $192 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $566 29 payments
  2. Lilly USA, LLC $500 37 payments
  3. Sanofi-Aventis U.S. LLC $491 13 payments
  4. Xeris Pharmaceuticals, Inc. $484 28 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $454 35 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $407 20 payments
  7. Radius Health, Inc. $382 18 payments
  8. Alexion Pharmaceuticals, Inc. $367 15 payments
  9. Mannkind Corporation $322 16 payments
  10. Amgen Inc. $254 14 payments
  11. Other $1,912 93 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,139 318 payments
Products named General payments · program years 2022–2025
  1. Kerendia $454 35 payments
  2. Tymlos $382 18 payments
  3. GVOKE HYPOPEN $378 23 payments
  4. TZIELD $369 6 payments
  5. STRENSIQ $342 14 payments
  6. AFREZZA $322 16 payments
  7. MOUNJARO $297 20 payments
  8. ISTURISA $215 9 payments
  9. SIGNIFOR LAR $215 9 payments
  10. Ozempic $213 15 payments
  11. Other $3,362 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,370

Median for Physician Assistant: 241

Drug cost

$629,185

Median for Physician Assistant: $4,110

Branded share of claims

56.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 172 $191,411
Mounjaro Tirzepatide Brand 89 $112,126
Jardiance Empagliflozin Brand 71 $81,249
Trulicity Dulaglutide Brand 35 $41,667
Farxiga Dapagliflozin Propanediol Brand 47 $37,694
Rybelsus Semaglutide Brand 29 $31,440
Tresiba Flextouch U-100 Insulin Degludec Brand 21 $20,070
Tradjenta Linagliptin Brand 20 $18,693
Cinacalcet Hcl Generic 34 $17,744
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 33 $16,799

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $203
  • Lilly USA, LLC $151
$354 71 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $340
$340 — —
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $211
$211 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $209
$209 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $183
$183 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record